US 12,459,922 B2
PARP7 inhibitors
Jayaraman Chandrasekhar, Redmond, WA (US); Jonah J. Chang, Woodinville, WA (US); Kevin S. Currie, North Bend, WA (US); Stephen D. Holmbo, Kirkland, WA (US); Jesse M. Jacobsen, Seattle, WA (US); David L Kukla, Newcastle, WA (US); Seung H. Lee, Sammamish, WA (US); Yasamin Moazami, Seattle, WA (US); Leena B. Patel, Seattle, WA (US); Thomas J. Paul, Snohomish, WA (US); Stephane Perreault, Brier, WA (US); Patrick J. Salvo, Burien, WA (US); Jennifer A. Treiberg, Redmond, WA (US); and Heath A. Weaver, Seattle, WA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Jan. 26, 2023, as Appl. No. 18/160,082.
Claims priority of provisional application 63/385,303, filed on Nov. 29, 2022.
Claims priority of provisional application 63/378,647, filed on Oct. 6, 2022.
Claims priority of provisional application 63/304,093, filed on Jan. 28, 2022.
Prior Publication US 2023/0365529 A1, Nov. 16, 2023
Int. Cl. C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01)] 16 Claims
 
1. A compound, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, which is:

OG Complex Work Unit Chemistry